Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00669)
Name
Thalidomide
Synonyms    Click to Show/Hide the Synonyms of This API
thalidomide; 50-35-1; Thalomid; Sedoval; 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (+/-)-THALIDOMIDE; Corronarobetin; Psycholiquid; Psychotablets; Theophilcholine; Algosediv; Asmadion; Bonbrain; Calmorex; Contergan; Distaval; Ectiluran; Enterosediv; Gastrinide; Glutanon; Hippuzon; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Nevrodyn; Noctosediv; Pantosediv; Polygripan; Profarmil; Quetimid; Quietoplex; Sandormin; Sedimide; Sedisperil; Shinnibrol; Softenil; Softenon; Talargan; Talismol; Telargean; Tensival; Thalinette; Valgraine; Asmaval; Calmore; Glupan; Grippex; Imidene; Isomin; Kevadon; Nibrol; Noxodyn; Pangul; Sleepan; Slipro; Talimol; Telagan; Thalin; Valgis; Yodomin; N-Phthaloylglutamimide; Predni-Sediv; Imida-lab; Poly-Giron; Sedalis sedi-lab; Shin-naito S; Neaufatin; Asidon 3; Pro-ban M; Imidan (peyta); N-Phthalylglutamic acid imide; Ulcerfen; 3-Phthalimidoglutarimide; alpha-Phthalimidoglutarimide; Bonbrrin; Distaxal; Distoval; Talidomida; Kedavon; (+-)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; Thalidomide Celgene; NSC-66847; alpha-N-Phthalylglutaramide; N-(2,6-Dioxo-3-piperidyl)phthalimide; Glutarimide, 2-phthalimido-; N-Phthalyl-glutaminsaeure-imid; alpha-(N-Phthalimido)glutarimide; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-; 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline; .alpha.-N-Phthalylglutaramide; Phthalimide, N-(2,6-dioxo-3-piperidyl)-; 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; MFCD00153873; CHEMBL468; Thalidomide (soluble form); 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; .alpha.-Phthalimidoglutarimide; 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; Thalomide; (+-)-N-(2,6-Dioxo-3-piperidyl)phthalimide; CHEBI:74947; .alpha.-(N-Phthalimido)glutarimide; 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; NSC66847; 2-(2,6-Dioxo-piperidin-3-yl)-isoindole-1,3-dione; NSC-527179; Pro-Bam M; N-(2,6-dioxo-3-piperidinyl)phthalimide; NCGC00015989-09; Talidomide [DCIT]; Thalidomidum; Neurosedyn; Sedalis; Talidomide; Telargan; DSSTox_CID_2524; DSSTox_RID_76611; DSSTox_GSID_22524; Talidomida [INN-Spanish]; Thalidomidum [INN-Latin]; Thalidomine USP26; Synovir; Talizer; (?)-Thalidomide; Thaled; Phthalimide,6-dioxo-3-piperidyl)-; ENMD 0995; WLN: T56 BVNVJ C- DT6VMVTJ; Thalomid (TM); Thalomid (TN); 1012310-87-0; Thalidomide Pharmion; Thaled (TN); N-Phthalyl-glutaminsaeure-imid [German]; N-Phthalimidoglutamic acid imide; HSDB 3586; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-; SR-01000076184; EINECS 200-031-1; NSC 527179; BRN 0030233; Celgene; Pharmion; Talinol; Thalidomide (JAN/USP/INN); AI3-50606; CCRIS 8148; (y)-Thalidomide; Thalidomide,(S); CAS-50-35-1; Prestwick_463; Thalidomide [USAN:USP:INN:BAN:JAN]; (A+/-)-Thalidomide; Prestwick0_000192; Prestwick1_000192; Prestwick2_000192; Prestwick3_000192; Spectrum2_000707; Spectrum3_001715; Spectrum4_001087; Spectrum5_001791; (.+/-.)-Thalidomide; UPCMLD-DP139; Thalomid (TN) (Celgene); SCHEMBL7581; NCIOpen2_003188; Lopac0_001224; BSPBio_000143; BSPBio_001156; BSPBio_003330; KBioGR_000496; KBioGR_001474; KBioGR_002322; KBioSS_000496; KBioSS_002324; 2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; MLS000069353; ARONIS24496; DivK1c_000051; SPECTRUM1503607; SPBio_000893; SPBio_002064; BPBio1_000159; GTPL7327; DTXSID9022524; SCHEMBL15197560; UPCMLD-DP139:001; HMS500C13; KBio1_000051; KBio2_000496; KBio2_002322; KBio2_003064; KBio2_004890; KBio2_005632; KBio2_007458; KBio3_000911; KBio3_000912; KBio3_002550; KBio3_002802; cMAP_000022; NINDS_000051; Bio1_000387; Bio1_000876; Bio1_001365; Bio2_000418; Bio2_000898; HMS1362J17; HMS1568H05; HMS1792J17; HMS1922E12; HMS1990J17; HMS2090O05; HMS2093G15; HMS2095H05; HMS2234C07; HMS3259C22; HMS3263F10; HMS3266F13; HMS3373E06; HMS3373G15; HMS3403J17; HMS3414F19; HMS3654A20; HMS3678F19; HMS3712H05; HMS3884I05; Pharmakon1600-01503607; BCP19772; NSC91729; NSC91730; Tox21_110275; Tox21_300580; Tox21_501224; (+/-)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (+-)-; AC-917; ANW-53225; BBL023439; BDBM50070114; CCG-39878; NSC-91729; NSC-91730; NSC527179; NSC758479; STL356025; ( inverted question mark)-Thalidomide; AKOS009529198; Tox21_110275_1; CS-1084; DB01041; LP01224; MCULE-6327754946; NC00600; NSC-758479; SDCCGSBI-0051191.P004; (+/-)-Thalidomide, >=98%, powder; IDI1_000051; IDI1_002173; NCGC00015989-03; NCGC00015989-04; NCGC00015989-05; NCGC00015989-06; NCGC00015989-07; NCGC00015989-08; NCGC00015989-10; NCGC00015989-11; NCGC00015989-12; NCGC00015989-13; NCGC00015989-14; NCGC00015989-16; NCGC00015989-17; NCGC00015989-29; NCGC00024708-02; NCGC00024708-03; NCGC00024708-04; NCGC00024708-05; NCGC00024708-06; NCGC00024708-07; NCGC00024708-08; NCGC00024708-09; NCGC00024708-10; NCGC00024708-11; NCGC00254343-01; NCGC00261909-01; AK-91024; AS-12367; BP-30256; HY-14658; NCI60_023904; SMR000058524; SY052614; WLN: T56 BVNVJ C- DT6VMVTJ -D; WLN: T56 BVNVJ C- DT6VMVTJ -L; SBI-0051191.P003; AB0011813; DB-051759; Phthalimide,6-dioxo-3-piperidyl)-, (+)-; Phthalimide,6-dioxo-3-piperidyl)-, (-)-; AB00052362; EU-0101224; FT-0600001; FT-0602275; FT-0631211; FT-0675130; ST51039042; SW196678-4; isopropyl (3,4-dichlorophenyl)carbamodithioate; Phthalimide,6-dioxo-3-piperidyl)-, D-(+)-; Phthalimide,6-dioxo-3-piperidyl)-, L-(-)-; (+/-)-N-(2,6-dioxo-3-piperidyl)phthalimide; C07910; D00754; J90042; M-1523; AB00052362-11; AB00052362-12; AB00052362-13; AB00052362_14; AB00052362_15; 153T873; Q203174; SR-01000076184-1; SR-01000076184-3; SR-01000076184-5; SR-01000076184-8; Thalidomide N-(2,6-Dioxopiperidin-3-yl)phthalimide; W-105969; BRD-A93255169-001-04-4; BRD-A93255169-001-06-9; BRD-A93255169-001-24-2; Z1550675451; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (R)-; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (S)-; 2-(2,6-dioxoazaperhydroin-3-yl)benzo[c]azoline-1,3-dione; 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione #; (??)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; [(R,S)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; Thalidomide, United States Pharmacopeia (USP) Reference Standard; ( inverted question mark)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
Clinical Status
Approved
Disease Indication Multiple myeloma ICD-11: 2A83 [1]
PubChem CID
5426
Formula
C13H10N2O4
Canonical SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
InChI
1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
InChIKey
UEJJHQNACJXSKW-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5426"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 258.23 Topological Polar Surface Area 83.6
XlogP 0.3 Complexity 449
Heavy Atom Count 19 Rotatable Bond Count 1
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Thalidomide 100 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
          Thalidomide 150 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
          Thalidomide 200 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
          Thalidomide 50 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
References
1 FDA label for approved thalidomide from the official website of the U.S. Food and Drug Administration.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.